Home›Trial›NCT07259317
🔬NCT07259317Phase 2RECRUITING

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Study Summary

This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).

Conditions
AdenocarcinomaCarcinoma, Pancreatic Ductal
Interventions / Drugs
Relacorilant 150 mg once daily (QD)Nab-paclitaxel 100 mg/m^2Gemcitabine 1000 mg/m^2
View on ClinicalTrials.gov ↗
Sponsor
CORT
Corcept Therapeutics
Endocrinology
C59/100
Study Details
Enrollment60 participants
Primary Completion—
Lead SponsorCorcept Therapeutics
Data Retrieved2026-04-11 04:10:22.666689+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.